Oligonucleotides, compositions and methods thereof
Inventors
Zhang, Jason Jingxin • Iwamoto, Naoki • Francis, Christopher J. • Vargeese, Chandra • Butler, David Charles Donnell • Divakaramenon, Sethumadhavan • Lu, Genliang • Marappan, Subramanian
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described. In some embodiments, no immune modulation is desired, and the present disclosure provides methods of identifying chirally controlled oligonucleotide compositions which have decreased immune modulation.
Core Innovation
The disclosure identifies backbone stereochemistry in chiral internucleotidic linkages, particularly phosphorothioates within CpG motifs, as a critical determinant of oligonucleotide immune-modulatory activity including TLR9 agonism and antagonism. It provides chirally controlled compositions comprising a predetermined level of oligonucleotides of an individual type defined by base sequence, backbone-linkage pattern, backbone chiral-center pattern, and backbone phosphorus modifications. Each oligonucleotide comprises a common CpG region motif with chiral internucleotidic linkages that modulate activation across TLR9 systems.
The disclosure provides methods for evaluating TLR9 activation for chirally controlled compositions relative to a reference composition to determine reduced activation, as well as administering these compositions to measure the resulting TLR9 response. Structural variations include lipid conjugates, gapmer architectures, and internucleotidic modifications designed to alter cellular uptake, clearance, and immune response profiles. These configurations demonstrate that backbone chiral architecture substantially influences TLR9-mediated biological outcomes beyond nucleotide base sequence alone.
Claims Coverage
The claims identify two independent claims encompassing two inventive features directed to chirally controlled CpG oligonucleotide compositions and TLR9 response.
Comparative assessment of TLR9 activation against a reference composition
Independent claim 1 covers independently assessing TLR9 activation for chirally controlled oligonucleotide compositions and a reference oligonucleotide composition in a system, and determining that a chirally controlled composition displays reduced TLR9 activation compared with the reference composition, wherein each composition comprises a predetermined level of an oligonucleotide type defined by base sequence, backbone-linkage pattern, backbone chiral-center pattern, and backbone phosphorus-modification pattern with a common CpG region motif.
Administration of a chirally controlled composition and measurement of TLR9 response
Independent claim 18 covers administering a chirally controlled oligonucleotide composition comprising a predetermined level of an individual oligonucleotide type defined by base sequence, backbone-linkage pattern, backbone chiral-center pattern, and backbone phosphorus-modification pattern with a common CpG region motif, and measuring the resulting TLR9 response.
Together, the independent claims cover comparative assessment to identify chirally controlled oligonucleotide compositions displaying reduced TLR9 activation relative to a reference composition and administration of a chirally controlled composition accompanied by measurement of the TLR9 response.
Stated Advantages
Potentially altered immune-modulatory activity, including TLR9 agonism or antagonism, wherein internucleotidic linkage stereochemistry within CpG motifs modulates activity independently of base sequence.
The screening result identifies chirally controlled CpG oligonucleotides displaying increased, decreased, or reduced TLR9 activation relative to a reference composition.
Potentially reduced toxicity, improved stability, improved protein binding, and improved delivery, pharmacokinetics, and tissue distribution.
Lipid conjugation is stated to reduce TLR9 agonist activity, potentially enhance TLR9 antagonist activity (including antagonism of ODN2006-mediated activity), and improve muscle delivery and clearance.
Additional phosphorus modifications are described as supporting prodrug release, cellular uptake, circulation time, and targeting.
Reduced inflammation is reported following oral administration of WV-499 in a mouse inflammatory bowel disease model.
Documented Applications
Assessing and comparing TLR9 activation by chirally controlled CpG oligonucleotide compositions and reference compositions, including identifying compositions displaying reduced TLR9 activation.
Administering a chirally controlled oligonucleotide composition determined to have reduced TLR9 activation to a subject.
Administering a chirally controlled oligonucleotide composition and measuring the resulting TLR9 response.
Therapeutic and research applications including transcript-splicing modulation, transcript targeting, and treatment of Duchenne muscular dystrophy with oligonucleotides targeting DMD exons 23 and 51, and spinal muscular atrophy.
Use of CpG oligonucleotides as vaccine adjuvants and in therapies for cancer, infectious diseases, inflammatory conditions, and autoimmune disorders.
In vivo evaluation of WV-499 in a TNBS-induced mouse inflammatory bowel disease model.
Oligonucleotide designs featuring lipid conjugation or substituents configured to support autorelease, prodrug behavior, cell entry, targeting, and muscle delivery.
Interested in licensing this patent?